Melanoma cancer vaccine: Phase II started

NAL began an open-label, U.S. Phase II trial in 100 patients with stage IIb-III melanoma or stage IV melanoma where the metastatic lesion(s) has been removed to evaluate immunogenicity of the vaccine ...